X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PLETHICO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PLETHICO PHARMA ASTRAZENECA PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 95.2 -1.1 - View Chart
P/BV x 13.6 0.0 80,879.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PLETHICO PHARMA
Mar-14
ASTRAZENECA PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285395 325.4%   
Low Rs63431 2,025.6%   
Sales per share (Unadj.) Rs189.6604.4 31.4%  
Earnings per share (Unadj.) Rs-0.232.5 -0.6%  
Cash flow per share (Unadj.) Rs3.851.3 7.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6473.6 14.5%  
Shares outstanding (eoy) m25.0034.08 73.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.4 1,435.4%   
Avg P/E ratio x-4,712.76.6 -71,826.5%  
P/CF ratio (eoy) x249.64.2 6,011.3%  
Price / Book Value ratio x14.00.5 3,106.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9887,262 330.3%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,6051,596 100.5%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,74020,598 23.0%  
Other income Rs m92386 23.8%   
Total revenues Rs m4,83220,984 23.0%   
Gross profit Rs m-1302,818 -4.6%  
Depreciation Rs m101642 15.8%   
Interest Rs m01,593 0.0%   
Profit before tax Rs m-139969 -14.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5-138 -3.7%   
Profit after tax Rs m-51,107 -0.5%  
Gross profit margin %-2.713.7 -20.0%  
Effective tax rate %-3.7-14.3 25.6%   
Net profit margin %-0.15.4 -2.0%  
BALANCE SHEET DATA
Current assets Rs m2,72618,877 14.4%   
Current liabilities Rs m2,43511,896 20.5%   
Net working cap to sales %6.133.9 18.1%  
Current ratio x1.11.6 70.6%  
Inventory Days Days7436 205.2%  
Debtors Days Days41198 20.6%  
Net fixed assets Rs m1,0359,861 10.5%   
Share capital Rs m50341 14.7%   
"Free" reserves Rs m94212,331 7.6%   
Net worth Rs m1,71616,139 10.6%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m4,15633,146 12.5%  
Interest coverage xNM1.6-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.6 183.5%   
Return on assets %-0.18.1 -1.5%  
Return on equity %-0.36.9 -4.3%  
Return on capital %012.3 0.0%  
Exports to sales %5.721.4 26.7%   
Imports to sales %6.515.2 42.4%   
Exports (fob) Rs m2704,402 6.1%   
Imports (cif) Rs m3063,136 9.8%   
Fx inflow Rs m3754,402 8.5%   
Fx outflow Rs m4703,184 14.8%   
Net fx Rs m-961,219 -7.8%   
CASH FLOW
From Operations Rs m-82,437 -0.3%  
From Investments Rs m-146-6,265 2.3%  
From Financial Activity Rs m8622,490 34.6%  
Net Cashflow Rs m709-1,337 -53.0%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.3 7.0%  
FIIs % 15.7 5.5 285.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 7.5 121.3%  
Shareholders   12,856 10,665 120.5%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS